model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
GPT-5.1,protocolSection.identificationModule.nctId,TP,TP,NCT02981602,NCT02981602,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
GPT-5.1,protocolSection.identificationModule.orgStudyIdInfo.type,EV,EV,,OTHER,,,,OrgStudyIdType,protocolSection.identificationModule.orgStudyIdInfo.type,True,False,True,False,False,False
GPT-5.1,protocolSection.identificationModule.orgStudyIdInfo.link,EV,EV,,https://www.gsk-studyregister.com/en/trial-details/?id=205695,,,,OrgStudyIdLink,protocolSection.identificationModule.orgStudyIdInfo.link,True,False,True,False,False,False
GPT-5.1,protocolSection.identificationModule.secondaryIdInfos[0].link,EV,EV,,,,,,SecondaryIdLink,protocolSection.identificationModule.secondaryIdInfos.link,True,False,True,False,False,False
GPT-5.1,protocolSection.identificationModule.briefTitle,TP,TP,"Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection",A Phase 2 Study of Bepirovirsen in Individuals With Chronic Hepatitis B,True,0.84,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
GPT-5.1,protocolSection.identificationModule.officialTitle,TP,TP,"A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Escalation Study to Examine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ISIS 505358 in Treatment-Naïve Patients With Chronic HBV Infection","A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Trial of Bepirovirsen in Treatment-Naïve and Virally Suppressed Individuals With Chronic Hepatitis B Virus Infection",True,0.86,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
GPT-5.1,protocolSection.identificationModule.acronym,EV,EV,,,,,,Acronym,protocolSection.identificationModule.acronym,True,False,True,False,False,False
GPT-5.1,protocolSection.descriptionModule.briefSummary,TP,TP,To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection,"This phase 2, double-blind, randomized, placebo-controlled, first‑in‑human trial evaluated bepirovirsen, an antisense oligonucleotide that targets hepatitis B virus (HBV) RNA, in adults with chronic hepatitis B infection. The study enrolled both treatment‑naïve patients and patients already on stable nucleos(t)ide analog (NA) therapy. Participants received subcutaneous bepirovirsen (150 mg or 300 mg) or placebo twice weekly for 2 weeks then once weekly for 2 weeks, followed by 26 weeks of follow‑up. The main goal was to assess safety and tolerability; a key secondary goal was to measure antiviral activity, particularly change in hepatitis B surface antigen (HBsAg) levels. Bepirovirsen produced dose‑dependent reductions in HBsAg and HBV DNA, with significant effects at 300 mg, and a generally favorable safety profile, though transient alanine aminotransferase (ALT) flares were observed and appeared related to antiviral activity.",True,0.83,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
GPT-5.1,protocolSection.descriptionModule.detailedDescription,TP,FP,This study examines the effects of IONIS-HBVRx or placebo (3:1 randomization) administered subcutaneously to treatment-naïve patients who are chronically infected with HBV and the effects of subsequent nucleos(t)ide analogue treatment on these patients.,"This first‑in‑human, phase 2, double‑blind, randomized, placebo‑controlled, dose‑escalation trial (NCT02981602; ISIS 505358‑CS3; GSK study 205695) investigated the safety, tolerability, and antiviral activity of bepirovirsen (GSK3228836) in adults with chronic hepatitis B (CHB). Bepirovirsen is a 2′‑O‑methoxyethyl (2′‑MOE) gapmer antisense oligonucleotide with phosphorothioate linkages that binds a conserved sequence present in all HBV mRNAs and pregenomic RNA, leading to RNase H–mediated cleavage, and reductions in HBV RNA, HBV DNA, and viral proteins, including hepatitis B surface antigen (HBsAg).

Eligible participants had chronic HBV infection for at least 6 months and serum HBsAg ≥50 IU/mL; both hepatitis B e antigen (HBeAg)–positive and HBeAg‑negative patients were included. Treatment‑naïve participants required HBV DNA ≥2×10³ IU/mL; on‑NA participants had HBV DNA below the lower limit of quantitation while on stable tenofovir disoproxil fumarate or entecavir for ≥12 months.

A total of 31 patients with CHB were enrolled at centers in Hong Kong and the Republic of Korea: 24 treatment‑naïve (randomized to placebo, bepirovirsen 150 mg, or bepirovirsen 300 mg) and 7 on stable NA therapy (randomized to placebo or bepirovirsen 300 mg). Study drug was administered subcutaneously six times over 4 weeks: twice weekly during weeks 1 and 2 (days 1, 4, 8, 11) and once weekly during weeks 3 and 4 (days 15 and 22). Treatment‑naïve patients then initiated NA therapy on day 29; on‑NA patients continued their background NA. All participants were followed through day 211 (week 31).

The primary objective was to assess safety and tolerability, including adverse events (AEs), laboratory parameters (notably liver enzymes, C‑reactive protein, coagulation tests), vital signs, ECGs, and physical examinations. Secondary objectives included evaluation of antiviral activity: changes from baseline to day 29 and week 31 in serum HBsAg, plasma HBV DNA, and serum HBeAg (in HBeAg‑positive patients), as well as the proportion of patients achieving HBsAg or HBeAg loss. Exploratory endpoints included HBV RNA, hepatitis B core‑related antigen (HBcrAg), and seroconversion to anti‑HBs or anti‑HBe antibodies.

Bepirovirsen was generally well tolerated. The most common treatment‑emergent adverse events were mild to moderate injection‑site reactions (erythema, swelling, pruritus, bruising, pain) and pyrexia. Transient elevations in C‑reactive protein were observed after initial dosing, consistent with known class effects of phosphorothioate oligonucleotides, without consistent associated symptoms. Transient, modest prolongations of activated partial thromboplastin time occurred but were not clinically significant and were not associated with bleeding. No complement activation–related findings were observed.

ALT flares (ALT ≥2× upper limit of normal) occurred in 8 of 18 bepirovirsen‑treated treatment‑naïve patients and 3 of 5 bepirovirsen‑treated on‑NA patients but in no placebo recipients. These flares were transient and self‑resolving, sometimes reaching ≥10× ULN, and occurred in the absence of bilirubin elevations suggesting liver failure. ALT elevations tended to coincide with, or follow, substantial reductions in HBsAg and HBV DNA, and were rare in patients without HBsAg decline or in healthy volunteer studies, supporting the interpretation that ALT flares reflect pharmacologic, possibly immune‑mediated, clearance of infected hepatocytes rather than direct drug toxicity. One patient had a grade 4 ALT increase (ALT 781 U/L) accompanied by AST elevation but remained asymptomatic and recovered without lasting sequelae.

Antiviral activity was dose‑dependent. Among treatment‑naïve patients, mean reductions from baseline to day 29 with bepirovirsen 150 mg were −0.50 log10 IU/mL for HBsAg and −0.38 log10 IU/mL for HBV DNA, which were not statistically significant versus placebo. With bepirovirsen 300 mg, mean reductions were −1.56 log10 IU/mL for HBsAg (P=0.001 vs placebo) and −1.66 log10 IU/mL for HBV DNA (P<0.001 vs placebo). No meaningful HBsAg or HBV DNA reductions occurred in placebo recipients. Six of 12 treatment‑naïve patients on 300 mg had ≥1.0 log10 HBsAg reduction by day 29 (three had ≥3.0 log10 reduction), and two achieved transient or more prolonged HBsAg loss (HBsAg below 0.05 IU/mL), with variable durability after treatment cessation.

In on‑NA patients receiving bepirovirsen 300 mg, mean HBsAg reduction was −1.99 log10 IU/mL by day 29. Three of four evaluable on‑NA patients experienced ≥3.0 log10 HBsAg declines; two achieved HBsAg loss, one with more sustained suppression through week 31 while maintaining a marked reduction versus baseline. Baseline HBV RNA and HBcrAg levels in on‑NA patients were low or near assay limits, consistent with effective NA therapy, limiting detailed interpretation.

HBsAg and HBV DNA reductions occurred in both HBeAg‑positive and HBeAg‑negative patients, but log10 declines were generally greater in HBeAg‑negative patients, who also had lower baseline antigen and viral loads. All four patients who achieved HBsAg loss were HBeAg‑negative. Post hoc analyses showed that patients with larger HBsAg reductions often had parallel decreases in HBV RNA and HBcrAg, supporting on‑target inhibition of HBV transcription. Minimal changes in HBeAg were seen overall, with more substantial reductions observed in a minority of patients.

Transient, treatment‑emergent anti‑HBs antibodies were detected in a subset of bepirovirsen‑treated patients, especially those with larger HBsAg reductions, consistent with unmasking of pre‑existing or newly generated antibodies once circulating HBsAg levels declined. Anti‑HBe seroconversion was rare but observed in isolated cases with sustained HBeAg decline.

Sequencing of HBV DNA or RNA from selected patients at baseline, day 29, and day 113 showed no changes in the bepirovirsen binding site, suggesting that virologic responses or non‑responses were not driven by loss of the target sequence.

Overall, 4 weeks of bepirovirsen treatment at 300 mg induced rapid, sometimes profound, and variably sustained reductions in HBsAg and HBV DNA in both treatment‑naïve and virally suppressed CHB patients, with an acceptable safety and tolerability profile and ALT flares that appeared linked to antiviral activity. These findings support further clinical development of bepirovirsen, including studies of longer treatment durations and combination regimens aimed at achieving functional cure (sustained HBsAg loss with undetectable HBV DNA) in a broader chronic hepatitis B population.",False,0.34,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
GPT-5.1,protocolSection.conditionsModule.conditions,TP,FP,"['Hepatitis B', 'Chronic Hepatitis B Atypical']","['Hepatitis B, Chronic', 'Hepatitis B Virus Infection', 'Hepatocellular Carcinoma (risk factor context)', 'Liver Cirrhosis (risk factor context)']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
GPT-5.1,protocolSection.conditionsModule.keywords,TP,FP,"['Hepatitis', 'Chronic', 'HBV']","['Chronic Hepatitis B', 'Hepatitis B Virus', 'HBV', 'HBsAg', 'HBeAg', 'HBV DNA', 'HBV RNA', 'Hepatitis B core-related antigen', 'HBcrAg', 'Bepirovirsen', 'GSK3228836', 'Antisense oligonucleotides', ""2'-O-methoxyethyl oligonucleotides"", 'Phosphorothioate oligonucleotides', 'Nucleos(t)ide analogs', 'Tenofovir disoproxil fumarate', 'Entecavir', 'Functional cure', 'ALT flare', 'Viral suppression', 'Hepatitis B surface antigen loss', 'Seroconversion', 'Hepatocellular carcinoma prevention']",False,0.3333333333333333,partial,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
GPT-5.1,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.phases,TP,TP,['PHASE2'],['PHASE2'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"Phase 2, double-blinded, randomized, placebo-controlled, dose-escalation, parallel-group trial with three cohorts of treatment-naïve patients (placebo, bepirovirsen 150 mg, bepirovirsen 300 mg) and one exploratory parallel cohort of patients already on stable nucleos(t)ide analogue therapy (placebo, bepirovirsen 300 mg).",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,TRIPLE,DOUBLE,True,0.7,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"Double-blinded, placebo-controlled trial; all participants, study monitors, study center personnel and contract research organization personnel were blinded to treatment assignment.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
GPT-5.1,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,FP,"['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']","['PARTICIPANT', 'INVESTIGATOR']",False,0.6666666666666666,partial,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
GPT-5.1,protocolSection.designModule.enrollmentInfo.count,TP,TP,31,31,True,1.0,exact,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.armGroups[4].label,EV,EV,,On-NA placebo add-on,,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.armGroups[4].type,EV,EV,,PLACEBO_COMPARATOR,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.armGroups[4].description,EV,EV,,"Patients with chronic hepatitis B already receiving a stable nucleos(t)ide analog regimen (tenofovir disoproxil fumarate or entecavir) with suppressed HBV DNA, randomized to receive add-on placebo via subcutaneous injection on the same schedule as bepirovirsen (twice weekly during weeks 1 and 2 and once weekly during weeks 3 and 4), while continuing their background NA therapy throughout the study.",,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.armGroups[4].interventionNames,EV,EV,,"['Placebo', 'Background nucleos(t)ide analog therapy']",,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[3].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[4].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[3].name,EV,EV,,Nucleos(t)ide analog therapy (post-bepirovirsen),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[4].name,EV,EV,,Background nucleos(t)ide analog therapy,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[3].description,EV,EV,,"Standard-of-care nucleos(t)ide analog therapy, tenofovir disoproxil fumarate (TDF) or entecavir (ETV), initiated in treatment-naïve patients on day 29 after completion of the bepirovirsen/placebo dosing period and continued daily until end of study (week 31, day 211).",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[4].description,EV,EV,,"Stable background nucleos(t)ide analog therapy, either tenofovir disoproxil fumarate (TDF) or entecavir (ETV), taken for at least 12 months before enrollment and continued without change throughout the study in on-NA cohorts.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[3].armGroupLabels,EV,EV,,"['Treatment-naïve bepirovirsen 150 mg', 'Treatment-naïve bepirovirsen 300 mg', 'Treatment-naïve placebo']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
GPT-5.1,protocolSection.armsInterventionsModule.interventions[4].armGroupLabels,EV,EV,,"['On-NA bepirovirsen 300 mg add-on', 'On-NA placebo add-on']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Seroconversion to anti-HBs antibodies,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Seroconversion to anti-HBe antibodies,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Proportion of participants who become anti-HBs antibody positive based on a qualitative assay (cut-off ≥11.5 mIU/ml) during or after bepirovirsen treatment and subsequent nucleos(t)ide analog therapy.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,Proportion of participants who become anti-HBe antibody positive during or after bepirovirsen treatment and subsequent nucleos(t)ide analog therapy.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,"Assessed at day 29 and week 31 (day 211); additional samples at screening, day 1, day 57, and day 113.",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
GPT-5.1,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,"Assessed at day 29 and week 31 (day 211); additional samples at screening, day 1, day 57, and day 113.",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
GPT-5.1,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Age 18 to 70 years
* Chronic HBV infection ≥6 months (e.g., positive for serum HBsAg ≥ 6 months)
* Plasma HBV DNA ≥ 2 x 1000 IU/mL (HBV DNA adequately suppressed for exploratory nucleos(t)ide analogue experienced cohort)
* Serum HBsAg ≥ 50 IU/mL
* Exploratory nucleos(t)ide analogue experienced cohort only: currently taking and have been taking tenofovir or entecavir without changes in drug, dose level and/or frequency of administration for ≥ 12 months and expect to continue taking without change through to the end of their participation in this study

Exclusion Criteria:

* Current or prior receipt of anti-HBV nucleos(t)ide analogue therapy. Patients who have failed prior interferon treatment, greater than 6 months prior to Screening, may be evaluated for possible participation in the study (not applicable for exploratory nucleos(t)ide analogue experienced cohort)
* History of liver cirrhosis and/or evidence of cirrhosis as determined by any of the following:

  1. Liver biopsy (i.e., Metavir Score F4) within 2 years of Screening, or
  2. Fibroscan \> 12 KPa, within 12 months of Screening, or
  3. AST-to-Platelet Index (APRI) \> 2 and Fibrosure result \> 0.7 within 12 months of Screening For patients without a test for cirrhosis in the above timeframes, Fibroscan, or APRI and Fibrosure, may be performed during the screening period to rule out cirrhosis
* History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices
* History of liver disease other than Hepatitis B
* Co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis D virus (HDV)
* BMI \> 35 kg/m2
* History of, or suspected presence of vasculitis
* Received solid organ or bone marrow transplant
* Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone)
* Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein ≥ 200 ng/mL. If the screening alpha-fetoprotein is ≥ 50 ng/mL and \< 200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization
* Clinically-significant abnormalities aside from chronic HBV infection in medical history (e.g., previous acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, uncontrolled diabetes) or physical examination
* History of bleeding diathesis or coagulopathy
* History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa)
* History of excess alcohol consumption within 6 months of Screening
* History of drug abuse or dependence, or recreational use of drugs: within 3 months of Screening for soft drugs (such as marijuana) and within 1-year of Screening for hard drugs (such as cocaine, phencyclidine \[PCP\])","- Inclusion Criteria:
  - Chronic HBV infection ≥6 months.
  - Serum HBsAg ≥50 IU ml−1.
  - Both HBeAg-positive and HBeAg-negative patients could participate.
  - Treatment-naïve cohort: plasma HBV DNA ≥2 × 10^3 IU ml−1.
  - On-NA cohort: HBV DNA adequately suppressed (plasma or serum HBV DNA below LLOQ (20 IU ml−1)).
  - On-NA cohort: taking stable tenofovir disoproxil fumarate (TDF) or entecavir (ETV) for ≥12 months and expected to continue taking stable TDF or ETV without change through to the end of participation in the study.

- Exclusion Criteria:
  - History of liver cirrhosis and/or evidence of cirrhosis.
  - Liver failure.
  - Liver disease other than hepatitis B.
  - Gilbert’s syndrome or history of laboratory results consistent with Gilbert’s syndrome.
  - Extrahepatic disorders possibly related to HBV immune complexes.
  - Excess alcohol consumption.
  - Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV.
  - Screening laboratory values of ALT and AST >5× upper limit of normal (ULN).
  - Treatment-naïve cohort: current or prior receipt of anti-HBV nucleos(t)ide analog therapy.
  - Patients who had failed prior interferon treatment more than 6 months before screening may be evaluated for possible participation in the study (i.e., not an absolute exclusion).

- Note:
  - Full eligibility criteria are stated to be available in the Supplementary Methods, but those detailed criteria are not included in the provided text.",True,0.9,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
GPT-5.1,protocolSection.eligibilityModule.minimumAge,TP,FP,18 Years,N/A,False,0.0,success,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.maximumAge,TP,FP,70 Years,N/A,False,0.0,success,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
GPT-5.1,protocolSection.eligibilityModule.studyPopulation,EV,EV,,,,,,StudyPopulation,protocolSection.eligibilityModule.studyPopulation,True,False,True,False,False,False
GPT-5.1,protocolSection.eligibilityModule.samplingMethod,EV,EV,,,,,,SamplingMethod,protocolSection.eligibilityModule.samplingMethod,True,False,True,False,False,False
